Start Free Trial
Pricing
Log In
Log In
Upgrade browser for full Crunchbase experience. You're accessing Crunchbase in a browser that is no longer supported.
Learn More
Hillstar Bio Logo
Hillstar Bio Growth Score
70
CB Rank
31204
Heat Score
7
Hillstar Bio is developing precision immunotherapies to treat autoimmune diseases.
Founded
obfuscation
PrivateSeries A Boston, Massachusetts, United States11-50 hillstarbio.com/
Biotechnology
Health Care
Medical
Overview

Hillstar Bio
Total Funding
obfuscation
Growth Score
70
Heat Score
7

Total Funding
obfuscation
obfuscation
Series A raised
obfuscation
Growth Score70
-9 pts
in past quarter
Heat Score 7
-18 pts
in past quarter

Company Performance Metrics

Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Learn More >
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience

About Hillstar Bio

CB Rank
31204
Hillstar Bio is developing precision immunotherapies to treat autoimmune diseases.
Founded
obfuscation
PrivateSeries A Boston, Massachusetts, United States11-50 hillstarbio.com/
Biotechnology
Health Care
Medical

Funding Rounds

Series A
OBF
in
obfuscation

Details

Legal Name Hillstar Bio, Inc.
Operating Status Active
Company Type For Profit
About the Company
Hillstar Bio is developing precision immunotherapies to treat autoimmune diseases.
Contact Email info@hillstarbio.com
Predictions & Insights

Growth Insight

See this Growth Insight
Hillstar Bio is
Lorem
 to be growing
Top Contributing Factors
Recently Raised Funding

Growth Prediction

See this Growth Prediction
Top Contributing Factors
Key Employee Changes

Products & Services

HSB-101
A precision immunotherapy targeting TRBV9+ T cells for axial spondyloarthritis and related HLA-B27-mediated conditions.
Undisclosed Programs
A pipeline of precision immunotherapies targeting specific immune cell subsets for various autoimmune diseases.

Unlock More with Crunchbase Pro
  • Full access to financial & funding data on unlimited profiles
  • Export up to 2k results/month for analysis
  • Track market signals on competitors, products, and R&D
  • Preview private company insights and predictions
Financials

Company Funding

Total Funding Amount 
obfuscation
Number of Funding Rounds 1
Unlock company funding data, including rounds, dates, amounts, and investors.
Announced Date  
Transaction Name  
Number of Investors  
Money Raised  
Lead Investors  
Funding Type  
obfuscation
Series A - Hillstar Bio Logo
Series A - Hillstar Bio
5
obfuscation
— Series A
obfuscation
Series A - Hillstar Bio Logo
Series A - Hillstar Bio
5
obfuscation
— Series A
obfuscation
Series A - Hillstar Bio Logo
Series A - Hillstar Bio
5
obfuscation
— Series A
obfuscation
Series A - Hillstar Bio Logo
Series A - Hillstar Bio
5
obfuscation
— Series A
obfuscation
Series A - Hillstar Bio Logo
Series A - Hillstar Bio
5
obfuscation
— Series A

Funding Rounds

Total Funding Amount 
obfuscation
Number of Funding Rounds 1
Unlock company funding data, including rounds, dates, amounts, and investors.
Announced Date  
Transaction Name  
Number of Investors  
Money Raised  
Lead Investors  
Funding Type  
obfuscation
Series A - Hillstar Bio Logo
Series A - Hillstar Bio
5
obfuscation
— Series A
obfuscation
Series A - Hillstar Bio Logo
Series A - Hillstar Bio
5
obfuscation
— Series A
obfuscation
Series A - Hillstar Bio Logo
Series A - Hillstar Bio
5
obfuscation
— Series A
obfuscation
Series A - Hillstar Bio Logo
Series A - Hillstar Bio
5
obfuscation
— Series A
obfuscation
Series A - Hillstar Bio Logo
Series A - Hillstar Bio
5
obfuscation
— Series A

Investors

Market Intelligence
People
View Profiles & Contacts
Headcount 11-50 Board Members and Advisors 5

Board Members and Advisors

News

News and Press

News•Jan 29, 2026
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•Jan 29, 2026
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•May 30, 2025
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•May 28, 2025
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
Access a complete feed of recent news and press, from product launches to leadership changes.
Technology
View Tech Report

Monthly Web Visits

725
23.51%
 in past month

IT Spend

$304.2KThis year, Hillstar Bio is projected to spend $304.2K on IT, according to Aberdeen.

Active Website Tech Count

2Hillstar Bio is actively using 2 technologies for its website, according to BuiltWith. These include Common Crawl and  CommonCrawl Top 50m.
Sub-Organizations
Frequently Asked Questions

Where is Hillstar Bio's headquarters? Hillstar Bio is located in Boston, Massachusetts, United States.Who invested in Hillstar Bio? Hillstar Bio has 5 investors including Novo Holdings and  Frazier Life Sciences.When was the last funding round for Hillstar Bio? Hillstar Bio closed its last funding round on
obfuscation
from a Series A round.Who are Hillstar Bio's competitors? Alternatives and possible competitors to Hillstar Bio may include Sanofi, Bristol-Myers Squibb, and  MoonLake Immunotherapeutics.How much funding has Hillstar Bio raised to date? Hillstar Bio has raised
obfuscation
.
Who We Are
What We Do
Helpful Links
AI Content may contain mistakes and is not legal, financial or investment advice. Learn more.
Terms of Service | Privacy Policy | Sitemap | © 2026 Crunchbase Inc. All Rights Reserved.
(2e7868f 1)
|